Through the construction of a $700 million site in the Boston Seaport area, Eli Lilly aims to advance RNA based therapeutics. The facility, which will be known as the Lilly Institute for Genetic Medicine is part of the firm’s strategy to develop RNA based therapeutics using DNA-based technologies that can treat or prevent diseases that is difficult or not possible with traditional medicines. “The Institute will pair cutting-edge technologies with Lilly’s deep biological expertise in neuroscience, immunology, diabetes, and other…